NASDAQ · Biotechnology

Aerovate Therapeutics, Inc. (AVTE) Stock

$2.68 +0.00% NASDAQ: AVTE Healthcare

Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise focused on innovating therapies to enhance the well-being of patients afflicted with rare cardiopulmonary illnesses across the United States.

Valuation

MetricValue
Price$2.68
Market Cap$77.68M
P/E Ratio0.00
P/B Ratio0.52
P/S Ratio0.00
EPS (TTM)$-3193.30
52-Week High$884.98
52-Week Low$2.63
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-65.46%
ROA-51.74%
ROCE-51.69%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio14.29

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-23.0M$-53.0M$-81.0M$-75.0M$-114.0M
Net Profit$-23.0M$-52.0M$-76.0M$-70.0M$-127.0M
EPS$-1.87$-2.10$-2.87$-2.44$-3193.30
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$175.0M$135.0M$127.0M$80.0M$350.0M
Total Liabilities$3.0M$9.0M$18.0M$4.0M$17.0M
Cash$54.0M$22.0M$23.0M$34.0M$88.0M
Borrowings$1.0M$1.0M$1.0M$0$1.0M

Latest News

Atombit Signs Medallia Alliance to Generate Measurable Outcomes with AI-Driven Experience Intelligence PR Newswire · Jul 23, 2026 INTURAI HOSTS INVESTOR CALLS TODAY WITH PLATFORM DEMONSTRATIONS PR Newswire · Jul 23, 2026 Can an Aging America Escape the Nursing Home Default? "All Access hosted by Andy Garcia" Features Northland PACE Senior Care Services PR Newswire · Jul 23, 2026 IDnow Appoints Philippe Morel as Chief Executive Officer PR Newswire · Jul 23, 2026 ARTHEx Biotech Publishes First Demonstration of Improvement in a DM1-related Behavioral Alteration in a Preclinical Model of Myotonic Dystrophy Type 1 (DM1) PR Newswire · Jul 23, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-27.0M$-39.0M$-57.0M$-71.0M$-95.0M
Investing Cash Flow$-114.0M$7.0M$12.0M$56.0M$-247.0M
Financing Cash Flow$190.0M$0$1.0M$1.0M$361.0M
Net Cash Flow$50.0M$-32.0M$1.0M$10.0M$19.0M
Free Cash Flow$-28.0M$-39.0M$-57.0M$-71.0M$-95.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.17
FCF Yield-129.00%
Quick Ratio14.29
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACHLAchilles Therapeutics plc $1.48 +0.68% -0.85 $60.83M 0.00%
BLIBerkeley Lights, Inc. $1.20 -5.88% -0.85 $86.61M 0.00%
IGMSIGM Biosciences, Inc. $1.27 +0.00% 1.75 $77.50M 0.00%
IMDXInsight Molecular Diagnostics Inc. $4.70 -0.84% -3.13 $151.76M 0.00%
LABPLandos Biopharma, Inc. $22.93 +0.57% -6.55 $71.68M 0.00%

About Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise focused on innovating therapies to enhance the well-being of patients afflicted with rare cardiopulmonary illnesses across the United States. The company's principal effort involves advancing AV-101, an inhaled dry powder variant of imatinib, which is currently undergoing a Phase 2b/Phase 3 clinical study for the management of pulmonary arterial hypertension. Established in 2018, Aerovate Therapeutics, Inc. maintains its corporate headquarters in Waltham, Massachusetts.

Aerovate Therapeutics, Inc. is headquartered in US.

Aerovate Therapeutics, Inc. (AVTE) stock trades at $2.68 with a market capitalization of $77.68M. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.52, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.63 and $884.98, and currently trades 99.7% below its 52-week high.

On profitability, Aerovate Therapeutics, Inc. generates a return on equity (ROE) of -65.46%, return on capital employed of -51.69%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: aerovatetx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides